1 |
Danese S, Sans M, Fiocchi C. Inflammatory bowel disease; the role of environmental factors. Autoimmun Rev. 2004 ; 3(5) : 394–400.
DOI
ScienceOn
|
2 |
Han BH, Park MH, Han YN. Sedative activity of aporphine and cyclopeptide alkaoids isolated from the seed of Zizyphus vulgaris var. Spinosus, and the fruits and stem bark of Zizyphus jujuba var. Inermis in mice. J Pharm Soc Korea. 1993 ; 37(2) : 143–8.
|
3 |
Heo HJ, Park YJ, Suh YM, Choi SJ, Kim MJ, Cho HY, Chang YJ, Hong B, Kim HK, Kim E, Kim CJ, Kim BG, Shin DH. Effects of oleamide on choline acetyltransferase and cognitive activities. Biosci Biotechnol Biochem. 2003 ; 67(6) : 1284–91.
DOI
ScienceOn
|
4 |
Huang YL, Yen GC, Sheu F, Chau CF. Effects of water-soluble carbohydrate concentrate from Chinese jujube on different intestinal and fecal indices. J Agric Food Chem. 2008 ; 56(5) : 1734–9.
DOI
ScienceOn
|
5 |
Naftali T, Feingelernt H, Lesin Y, Rauchwarger A, Konikoff FM. Ziziphus jujuba extract for the treatment of chronic idiopathic constipation: a controlled clinical trial. Digestion. 2008;78(4):224–8.
DOI
ScienceOn
|
6 |
Hyams JS. Inflammatory bowel disease. Pediatr Rev. 2000 ; 21(9) : 291–5.
DOI
|
7 |
Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev. 2002 ; 15(1) : 79–94.
DOI
|
8 |
Lichtenstein GR, Rutgeerts P. Inflamm Bowel Dis. 2010 ; 16(2) : 338–46.
DOI
ScienceOn
|
9 |
Danese S, Sans M, Fiocchi C. Inflammatory bowel disease: the role of environmental factors. Autoimmun Rev. 2004 ; 3(5) : 394–400.
DOI
ScienceOn
|
10 |
Li Y, de Haar C, Chen M, Deuring J, Gerrits MM, Smits R, Xia B, Kuipers EJ, van der Woude CJ. Disease-related expression of the IL-6/STAT3/SOCS3 signaling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut. 2010 ; 59(2) : 227–35.
DOI
ScienceOn
|
11 |
Agoff SN, Brentnall TA, Crispin DA, Taylor SL, Raaka S, Haggitt RC, Reed MW, Afonina IA, Rabinovitch PS, Stevens AC, Feng Z, Bronner MP. The role of cyclooxygenase-2 in ulcerative colitis-associated neoplasia. Am J Pathol. 2000 ; 157(3) : 737–45.
DOI
ScienceOn
|
12 |
Roberts PJ, Morgan K, Miller R, Hunter JO, Middleton SJ. Neuronal COX-2 expression in human myenteric plexus in active inflammatory bowel disease. Gut. 2001 ; 48(4) : 468–72.
DOI
|
13 |
Ishiguro K, Ando T, Maeda O, Hasegawa M, Kadomatsu K, Ohmiya N, Niwa Y, Xavier R, Goto H. Paeonolattenuates TNBS-induced colitis by inhibiting NF-B and STAT1 transactivation. Toxicol Appl Pharmacol. 2006 ; 217(1) : 35–42.
DOI
ScienceOn
|
14 |
Choi CH, Kim YH, Kim YS, Ye BD, Lee KM, Lee BI, Jung SA, Kim WH, Lee HY, IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Korean J Gastroenterol. 2012 ; 59(2) : 118–40.
DOI
|
15 |
Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. Novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology. 1990 ; 98(3) : 694–702.
DOI
|
16 |
Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev. 2002 ; 15(1) : 79–94.
DOI
|
17 |
Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2000 ; 51 : 289–98.
DOI
ScienceOn
|
18 |
Murthy SN, Cooper HS, Shim H, Shah RS, Ibrahim SA, Sedergran DJ. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci. 1993 ; 38(9) : 1722–34.
DOI
|
19 |
Domènech E. Inflammatory bowel disease: current therapeutic options. Digestion. 2006 ; 73(1) : 67–76.
DOI
ScienceOn
|
20 |
Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 1993 ; 69(2) : 238–49.
|
21 |
Hendel J, Nielsen OH. Expression of cyclooxygenase-2 mRNA in active inflammatory bowel disease. Am J Gastroenterol. 1997 ; 92(7) : 1170–3.
|
22 |
Matuk R, Crawford J, Abreu MT, Targan SR, Vasiliauskas EA, Papadakis KA. The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004 ; 10(4) : 352–6.
DOI
ScienceOn
|